Last reviewed · How we verify
TLL-018 immediate-release tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TLL-018 immediate-release tablet (TLL-018 immediate-release tablet) — Hangzhou Highlightll Pharmaceutical Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TLL-018 immediate-release tablet TARGET | TLL-018 immediate-release tablet | Hangzhou Highlightll Pharmaceutical Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TLL-018 immediate-release tablet CI watch — RSS
- TLL-018 immediate-release tablet CI watch — Atom
- TLL-018 immediate-release tablet CI watch — JSON
- TLL-018 immediate-release tablet alone — RSS
Cite this brief
Drug Landscape (2026). TLL-018 immediate-release tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/tll-018-immediate-release-tablet. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing